Keros Therapeutics (KROS) News Today $17.03 +0.11 (+0.65%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Franklin Resources Inc. Trims Position in Keros Therapeutics, Inc. (NASDAQ:KROS)Franklin Resources Inc. lowered its holdings in Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) by 28.0% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 288,234 shares of the company's stock after sDecember 21 at 4:46 AM | marketbeat.comY Intercept Hong Kong Ltd Has $215,000 Holdings in Keros Therapeutics, Inc. (NASDAQ:KROS)Y Intercept Hong Kong Ltd decreased its position in shares of Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) by 90.3% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 3,694 shares of the company's stock after sellinDecember 19 at 4:10 AM | marketbeat.comKeros Therapeutics, Inc. (NASDAQ:KROS) Shares Sold by State Street CorpState Street Corp cut its stake in shares of Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) by 8.8% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 1,113,590 shares of the company's stock after selling 107,786 shares duringDecember 19 at 3:32 AM | marketbeat.comKeros Therapeutics: Trading At Essentially Cash Value, Target Of $23 Per ShareDecember 18, 2024 | seekingalpha.comKeros Therapeutics: Hold Through The DustDecember 18, 2024 | seekingalpha.comKeros Therapeutics, Inc. (NASDAQ:KROS) Receives Average Recommendation of "Moderate Buy" from BrokeragesKeros Therapeutics, Inc. (NASDAQ:KROS - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the fourteen research firms that are currently covering the stock, Marketbeat Ratings reports. Four equities research analysts have rated the stock with a hold rating and ten haveDecember 18, 2024 | marketbeat.comKeros Therapeutics (NASDAQ:KROS) Lowered to "Neutral" Rating by GuggenheimDecember 18, 2024 | americanbankingnews.comKeros Therapeutics (NASDAQ:KROS) Stock Price Down 5.7% on Analyst DowngradeDecember 18, 2024 | americanbankingnews.comKeros Therapeutics (NASDAQ:KROS) Trading Down 5.7% After Analyst DowngradeKeros Therapeutics (NASDAQ:KROS) Shares Down 5.7% Following Analyst DowngradeDecember 17, 2024 | marketbeat.comOppenheimer Lowers Keros Therapeutics (NASDAQ:KROS) Price Target to $63.00December 17, 2024 | americanbankingnews.comGuggenheim Downgrades Keros Therapeutics (KROS)December 16, 2024 | msn.comKeros Therapeutics (NASDAQ:KROS) Shares Gap Down on Analyst DowngradeKeros Therapeutics (NASDAQ:KROS) Shares Gap Down After Analyst DowngradeDecember 16, 2024 | marketbeat.comOppenheimer Cuts Keros Therapeutics (NASDAQ:KROS) Price Target to $63.00Oppenheimer cut their price target on shares of Keros Therapeutics from $102.00 to $63.00 and set an "outperform" rating on the stock in a report on Monday.December 16, 2024 | marketbeat.comGuggenheim Downgrades Keros Therapeutics (NASDAQ:KROS) to NeutralGuggenheim lowered Keros Therapeutics from a "buy" rating to a "neutral" rating in a report on Monday.December 16, 2024 | marketbeat.comAnalysts Offer Insights on Healthcare Companies: Keros Therapeutics (KROS), AnaptysBio (ANAB) and US Physical Therapy (USPH)December 16, 2024 | markets.businessinsider.comScotiabank Cuts Keros Therapeutics (NASDAQ:KROS) Price Target to $44.00December 16, 2024 | americanbankingnews.comKeros Therapeutics (NASDAQ:KROS) Given New $47.00 Price Target at HC WainwrightDecember 16, 2024 | americanbankingnews.comKeros Therapeutics (NASDAQ:KROS) Cut to "Market Perform" at William BlairDecember 15, 2024 | americanbankingnews.comBTIG Research Downgrades Keros Therapeutics (NASDAQ:KROS) to NeutralDecember 15, 2024 | americanbankingnews.comTruist Financial Issues a Buy Rating on Keros Therapeutics (KROS)December 14, 2024 | markets.businessinsider.comKeros Therapeutics Target of Unusually Large Options Trading (NASDAQ:KROS)December 14, 2024 | americanbankingnews.comKeros Therapeutics (NASDAQ:KROS) Price Target Lowered to $44.00 at ScotiabankScotiabank lowered their price target on Keros Therapeutics from $77.00 to $44.00 and set a "sector outperform" rating on the stock in a research note on Friday.December 13, 2024 | marketbeat.comKeros Therapeutics (NASDAQ:KROS) Sees Strong Trading Volume - Still a Buy?Keros Therapeutics (NASDAQ:KROS) Sees Strong Trading Volume - Time to Buy?December 13, 2024 | marketbeat.comBTIG Downgrades Keros Therapeutics (KROS)December 13, 2024 | msn.comHC Wainwright Cuts Keros Therapeutics (NASDAQ:KROS) Price Target to $47.00HC Wainwright reduced their target price on shares of Keros Therapeutics from $100.00 to $47.00 and set a "buy" rating for the company in a research report on Friday.December 13, 2024 | marketbeat.comTD Cowen downgrades Keros Therapeutics (KROS) to a HoldDecember 12, 2024 | markets.businessinsider.comKeros Therapeutics (KROS) was downgraded to a Hold Rating at BTIGDecember 12, 2024 | markets.businessinsider.comKeros stock plunges 76% on drug study halt over safety concernsDecember 12, 2024 | msn.comKeros Therapeutics (NASDAQ:KROS) Lowered to Hold Rating by TD CowenTD Cowen downgraded Keros Therapeutics from a "buy" rating to a "hold" rating in a research note on Thursday.December 12, 2024 | marketbeat.comKeros Therapeutics (NASDAQ:KROS) Hits New 52-Week Low - Should You Sell?Keros Therapeutics (NASDAQ:KROS) Hits New 52-Week Low - What's Next?December 12, 2024 | marketbeat.comKeros Therapeutics (NASDAQ:KROS) Downgraded to Neutral Rating by BTIG ResearchBTIG Research downgraded shares of Keros Therapeutics from a "buy" rating to a "neutral" rating in a research note on Thursday.December 12, 2024 | marketbeat.comKeros Therapeutics (NASDAQ:KROS) Stock Rating Lowered by William BlairWilliam Blair lowered Keros Therapeutics from an "outperform" rating to a "market perform" rating in a research report on Thursday.December 12, 2024 | marketbeat.comKeros Therapeutics halts dosing of blood pressure treatment after safety reviewDecember 12, 2024 | reuters.comKeros Therapeutics Announces Update on the Phase 2 TROPOS TrialDecember 12, 2024 | globenewswire.comWells Fargo Sticks to Its Buy Rating for Keros Therapeutics (KROS)December 12, 2024 | markets.businessinsider.comJanus Henderson Group PLC Grows Stake in Keros Therapeutics, Inc. (NASDAQ:KROS)Janus Henderson Group PLC increased its holdings in shares of Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) by 543.8% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 92,110 shares of the company's sDecember 10, 2024 | marketbeat.comKeros Therapeutics Presents Clinical Data from its Elritercept Program at the 66th American Society of Hematology Annual Meeting and ExpositionDecember 9, 2024 | globenewswire.comAnalysts Offer Insights on Healthcare Companies: Arcellx Inc (ACLX), Argenx Se (ARGX) and Keros Therapeutics (KROS)December 9, 2024 | markets.businessinsider.comCharles Schwab Investment Management Inc. Grows Stake in Keros Therapeutics, Inc. (NASDAQ:KROS)Charles Schwab Investment Management Inc. boosted its position in Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) by 14.3% in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 260,120 shares of the company's stock after purchasing aDecember 8, 2024 | marketbeat.comWedbush Equities Analysts Lift Earnings Estimates for KROSKeros Therapeutics, Inc. (NASDAQ:KROS - Free Report) - Research analysts at Wedbush upped their Q1 2025 earnings estimates for shares of Keros Therapeutics in a research report issued on Tuesday, December 3rd. Wedbush analyst Y. Zhong now anticipates that the company will post earnings of ($1.40)December 6, 2024 | marketbeat.comReadystate Asset Management LP Decreases Stock Holdings in Keros Therapeutics, Inc. (NASDAQ:KROS)Readystate Asset Management LP lowered its position in Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) by 96.0% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 4,603 shares of the company's stock after selling 109,22December 6, 2024 | marketbeat.comKeros Therapeutics (KROS) Receives a Buy from Piper SandlerDecember 6, 2024 | markets.businessinsider.comPoint72 Asset Management L.P. Increases Stake in Keros Therapeutics, Inc. (NASDAQ:KROS)Point72 Asset Management L.P. grew its stake in shares of Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) by 155.9% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 947,570 shares of the companDecember 5, 2024 | marketbeat.comParkman Healthcare Partners LLC Has $24.49 Million Position in Keros Therapeutics, Inc. (NASDAQ:KROS)Parkman Healthcare Partners LLC raised its holdings in shares of Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) by 112.3% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 421,782 shares of the company's stock aDecember 4, 2024 | marketbeat.comErste Asset Management GmbH Invests $1.17 Million in Keros Therapeutics, Inc. (NASDAQ:KROS)Erste Asset Management GmbH acquired a new stake in shares of Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The fund acquired 20,700 shares of the company's stock, valued at approximately $December 4, 2024 | marketbeat.comTakeda, Keros Therapeutics enter exclusive elritercept license agreementDecember 4, 2024 | markets.businessinsider.comKeros Therapeutics' Licensing Deal With Takeda Aligns With Broader Opportunity For Elritercept: AnalystDecember 3, 2024 | benzinga.comKeros Therapeutics, Takeda in Elritercept Licensing PactDecember 3, 2024 | marketwatch.comKeros Therapeutics Announces Global License Agreement with Takeda to Advance ElriterceptDecember 3, 2024 | markets.businessinsider.comHighVista Strategies LLC Purchases 12,899 Shares of Keros Therapeutics, Inc. (NASDAQ:KROS)HighVista Strategies LLC boosted its position in Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) by 32.9% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 52,107 shares of the company's stock after buying an additionaDecember 3, 2024 | marketbeat.com Get Keros Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KROS and its competitors with MarketBeat's FREE daily newsletter. Email Address URGENT: This Altcoin Opportunity Won’t Wait – Act Now (Ad)Crypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight. >> Register for the Workshop Now KROS Media Mentions By Week KROS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. KROS News Sentiment▼0.100.60▲Average Medical News Sentiment KROS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. KROS Articles This Week▼214▲KROS Articles Average Week Get Keros Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KROS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Merus News ACADIA Pharmaceuticals News Twist Bioscience News Vericel News MorphoSys News SpringWorks Therapeutics News Kymera Therapeutics News Zai Lab News Gemini Therapeutics News Vera Therapeutics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:KROS) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredRare "crisis signal" triggers for third time in U.S. marketA rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the...Stansberry Research | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredBuffett's Oil Bet + This 22% Dividend PlayWarren Buffett has been quietly amassing a massive position in oil stocks. But while Buffett's picks (Occid...Investors Alley | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Keros Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Keros Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
